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Summary
Background Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high mortality, uncertain 
cause, and few treatment options. Studies have identified a significant genetic risk associated with the development 
of IPF; however, mechanisms by which genetic risk factors promote IPF remain unclear. We aimed to identify 
genetic variants associated with IPF susceptibility and provide mechanistic insight using gene and protein 
expression analyses.
Methods We used a two-stage approach: a genome-wide association study in patients with IPF of European 
ancestry recruited from nine different centres in the UK and controls selected from UK Biobank (stage 1) 
matched for age, sex, and smoking status; and a follow-up of associated genetic variants in independent datasets 
of patients with IPF and controls from two independent US samples from the Chicago consortium and the 
Colorado consortium (stage 2). We investigated the effect of novel signals on gene expression in large 
transcriptomic and genomic data resources, and examined expression using lung tissue samples from patients 
with IPF and controls.
Findings 602 patients with IPF and 3366 controls were selected for stage 1. For stage 2, 2158 patients with IPF and 
5195 controls were selected. We identified a novel genome-wide significant signal of association with IPF 
susceptibility near A-kinase anchoring protein 13 (AKAP13; rs62025270, odds ratio [OR] 1·27 [95% CI 1·18–1·37], 
p=1·32 × 10–⁹) and confirmed previously reported signals, including in mucin 5B (MUC5B; rs35705950, OR 2·89 
[2·56–3·26], p=1·12 × 10–⁶⁶) and desmoplakin (DSP; rs2076295, OR 1·44 [1·35–1·54], p=7·81 × 10–²⁸). For 
rs62025270, the allele A associated with increased susceptibility to IPF was also associated with increased 
expression of AKAP13 mRNA in lung tissue from patients who had lung resection procedures (n=1111). We 
showed that AKAP13 is expressed in the alveolar epithelium and lymphoid follicles from patients with IPF, and 
AKAP13 mRNA expression was 1·42-times higher in lung tissue from patients with IPF (n=46) than that in lung 
tissue from controls (n=51).
Interpretation AKAP13 is a Rho guanine nucleotide exchange factor regulating activation of RhoA, which is known to 
be involved in profibrotic signalling pathways. The identification of AKAP13 as a susceptibility gene for IPF increases 
the prospect of successfully targeting RhoA pathway inhibitors in patients with IPF.
Funding UK Medical Research Council, National Heart, Lung, and Blood Institute of the US National Institutes of 
Health, Agencia Canaria de Investigación, Innovación y Sociedad de la Información, Spain, UK National Institute for 
Health Research, and the British Lung Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. 
Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, 
progressive, fibrotic lung disease of unknown cause with 
a poor prognosis. The incidence of IPF in the UK is about 
4·5–7·5 per 100 000 and is increasing,1 with a median 
survival of approximately 3 years.2,3 Since 2010, two new 
therapies, pirfenidone and nintedanib, have been 
approved for the treatment of IPF, but these treatments 
only slow disease progression and do not halt or reverse 
pulmonary fibrosis.4,5 Furthermore, these drugs are not 
universally effective and the mechanisms of their 
antifibrotic effects are unknown. Therefore, a detailed 
understanding of the genetic risk factors for IPF and their 
associated molecular pathways is urgently required.
The current theory suggests that IPF is characterised 
by initial damage to the alveolar epithelium, which then 
signals to various cell types, predominantly fibroblasts 
and macrophages, promoting tissue damage and 
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extra cellular matrix synthesis that leads to parenchymal 
destruction and alveolar replacement by dense fibrotic 
tissue.2 Studies from patients with familial pulmonary 
fibrosis have identified telomerase-related and surfactant 
protein-related genes that are associated with epithelial 
dysfunction.6–8 Similarly, genome-wide association 
studies (GWAS) of IPF have reported various 
independent genetic association signals related to 
epithelial cell function of genome-wide significance,9–12 
including lung defence (such as mucin 5B [MUC5B]), 
telomere maintenance (such as telomerase reverse 
transcriptase [TERT] and CST complex subunit [STN1]) 
and cell–cell adhesion (such as desmoplakin [DSP] and 
dipeptidyl peptidase 9 [DPP9]).13 Telomerase mutations 
are associated with short telomeres,8 which lead to 
increased disease progression,14 whereas MUC5B and 
Toll interacting protein (TOLLIP) variants are associated 
with reduced disease progression.10,15 However, these 
genetic abnormalities account for only about 30% of the 
genetic risk associated with IPF, and the molecular 
mechanisms that become dysregulated remain to be 
established.13
Identifying further genetic risk factors will enable the 
identification of molecular pathways involved in the 
pathogenesis of IPF that could potentially be targeted 
with novel treatments. Molecular targets with supporting 
genetic evidence are twice as likely to be successful in 
clinical development as those with no genetic support.16 
We designed and implemented the largest UK-based 
IPF case-control GWAS to date (stage 1) and followed up 
promising genetic association signals in two independent 
IPF case-control studies (stage 2). We aimed to identify 
genetic variants associated with IPF susceptibility and 
provide mechanistic insight into those genetic 
association signals using gene and protein expression 
analyses.
Methods
Study design
This GWAS used a two-stage approach to identify 
novel genome-wide significant signals associated with 
susceptibility to IPF. In stage 1, a GWAS was done 
using patients with IPF from nine different centres in 
the UK and controls from UK Biobank. Variants 
showing a significant association (p<5 × 10–⁶) in stage 1 
were then further analysed in independent samples of 
patients with IPF and controls from two US samples, 
the Colorado consortium and the Chicago consortium 
(stage 2). We defined statistically significant 
associations with susceptibility to IPF as variants that 
met genome-wide significance (p<5 × 10–⁸) after meta-
analysis of stages 1 and 2 together. Variants that 
became less significant in the meta-analysis than in 
stage 1 alone were not reported as showing an 
association.
Stage 1 comprised patients with IPF selected from nine 
different centres across the UK (appendix p 1). All 
diagnoses were made in accordance with accepted 
international criteria.17–19 Controls were selected from UK 
Biobank and were matched for age, sex, and smoking 
distributions, showed no evidence of having any interstitial 
lung disease, and had genetic data available (appendix p 1). 
Stringent quality control testing of all samples was done, 
such as removing individuals with poor call rates, 
heterozygosity outliers, duplicates, related individuals, 
ancestry outliers, and sex mismatches (appendix p 1). All 
individuals were of European ancestry.
Stage 2 comprised two additional independent case-
control studies that have been previously described by Noth 
and colleagues10 (Chicago consortium) and Fingerlin and 
colleagues11 (Colorado consortium). For both these studies, 
patients with IPF were diagnosed using American 
Thoracic Society and European Respiratory Society 
Research in context
Evidence before this study
We searched Web of Science between Aug 21, 2015, and 
June 7, 2017, with the search terms “pulmonary fibrosis” and 
“genome wide” with no restrictions on publication date or 
language. Previous genome-wide association studies 
(GWAS) have reported 16 independent signals associated, at 
genome-wide significance, with susceptibility to idiopathic 
pulmonary fibrosis (IPF). Although previous studies have 
shown that epithelial cell function, lung defence, cell–cell 
adhesion, and telomere maintenance might play important 
roles in IPF, the precise mechanisms through which the 
genes identified in previous GWAS promote IPF are still 
poorly understood.
Added value of this study
To our knowledge, this study is the largest genetic study of IPF 
done to date, bringing together 2760 patients with IPF and 
8561 controls. We present a novel genome-wide significant 
genetic association signal and novel gene expression data that 
implicate A-kinase anchoring protein 13 (AKAP13) as an IPF 
susceptibility gene. AKAP13 is a Rho guanine nucleotide 
exchange factor (RhoGEF) that regulates activation of Rho A. 
RhoA is a molecule with a known role in profibrotic signalling 
pathways; however, AKAP13 has not previously been 
implicated in the pathogenesis of IPF. These studies provide 
genetic veracity for targeting Rho signalling in IPF.
Implications of all the available evidence
The identification of an association between AKAP13, an 
epithelial RhoGEF, and IPF supports the role of epithelial 
processes in IPF pathogenesis. Furthermore, AKAP13 has a role 
in a pharmacologically tractable molecular pathway that could 
lead to new treatments for IPF.
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guidelines.17,18 All studies had appropriate institutional 
review board or ethics approval.
Procedures and statistical analysis
For stage 1, patients with IPF and a third of the UK 
Biobank controls were genotyped using the Affymetrix 
Axiom UK BiLEVE array (Affymetrix, Santa Clara, 
CA, USA). The remainder of the controls were genotyped 
using the Affymetrix Axiom UK Biobank array 
(95% identical to the UK BiLEVE array). Genotyping and 
imputation procedures for studies contributing to stage 1 
and 2 are described in the appendix p 1. Because the UK 
Biobank controls genotyped on the Axiom UK BiLEVE 
array had originally been selected on the basis of lung 
function and smoking behaviour, it was reasonable to 
assume that allele frequency differences between the 
controls genotyped on the two arrays could feasibly be 
driven by either technical array artefacts or genuine 
associations with lung function and smoking. To account 
for this in our analysis, and to avoid incorrectly reporting 
associations driven by array as associations with IPF 
susceptibility, we did additional sensitivity analyses 
(appendix p 2).
The genome-wide association analysis of IPF 
susceptibility was done assuming an additive genetic 
effect and conditioning on age, sex, and the first ten 
principal components to adjust for ancestry.20 The 
analysis was run using a score test because of its 
computational efficiency, using SNPTEST21 version 2.5.2. 
For variants with minor allele count less than 400 and 
score test p<5 × 10–³, the analysis was rerun using the 
Firth test using EPACTS22 version 3.2.4 (appendix p 2).
Independent variants reaching a threshold of 
p<5 × 10–⁶ in association testing in stage 1 were followed 
up in stage 2. Conditional analyses were used to identify 
additional independent signals in the same genomic 
region (appendix p 2).
In the Chicago consortium, analyses were done using 
the Firth test, adjusting for age and sex. In the Colorado 
consortium, analyses were done using the Firth test on a 
logistic regression model, adjusting for sex and the top 
three dimensions from a multidimensional scaling 
model.
For variants that were significantly associated with IPF 
susceptibility in stage 1 only after conditioning on 
another variant, the analysis was run in stage 2 
conditioning on the same variant. The results from 
these stage 2 studies were meta-analysed using a fixed-
effects model.
For variants that showed a significant (p<5 × 10–⁶) 
association with IPF risk in stage 1, available association 
test statistics from stages 1 and 2 were meta-analysed 
using a fixed-effects model. Signals that had genome-
wide significance (p<5 × 10–⁸) when meta-analysing 
stages 1 and 2 were reported as significantly associated 
with susceptibility to IPF. A Bayesian approach was used 
to fine-map those signals to create 95% credible sets (a 
set of variants that was 95% likely to contain the causal 
variant; appendix p 3).
To investigate whether the variants showing an 
association with susceptibility to IPF were also 
associated with survival time in IPF, a Cox proportional 
hazards model was fitted in a subset of the stage 1 
patients with IPF that had data for survival time. The 
model made adjustments for age, sex, the first 
ten principal components, and the recruiting study 
centre. Analysis was done using the Survival package in 
R version 2.2.3.
We searched for evidence that genetic variants 
associated with susceptibility to IPF were independently 
associated with expression of a particular gene, because 
an association could implicate a particular gene as the 
driver of the signal. Variants that were significantly 
associated with susceptibility to IPF and proxy variants 
(correlated with linkage disequilibrium r²>0·8) were 
investigated in three expression quantitative trait locus 
(eQTL) datasets: a lung eQTL database comprising 
individuals from three cohorts (University of British 
Columbia, Laval, and Groningen), a blood eQTL database, 
and in the Genotype-Tissue Expression project (GTEx) 
cohort (multiple tissues; appendix p 3).
RT-PCR gene expression analysis was done on RNA 
extracted from human lung tissues of 46 patients with 
IPF and 51 controls from the Lung Tissue Research 
Consortium using standard methods (appendix p 3). 
Initially, differential gene expression in the lung was 
compared between the patients with IPF and controls 
using two-tailed Student’s t test comparing the change in 
CT values between groups. Linear regression analysis was 
used to compare A-kinase anchoring protein 13 (AKAP13) 
expression in controls and patients with IPF while also 
controlling for age, smoking (ever or never and pack-
years), and sex.
Formalin-fixed paraffin-embedded human lung tissue 
sections were obtained from tissue distant from the 
tumour that was obtained during lung resection from 
controls and tissue from patients with IPF taken at either 
post-mortem examination or lung transplantation. 
Immunohistochemistry was done using standard 
methods (appendix p 3).
We performed in-silico analyses to establish whether 
known drugs target the proteins identified in the 
genome-wide and expression analyses or the proteins 
that interact with them (appendix p 4).
Role of the funding source
The funders had no role in the study design. 
GlaxoSmithKline Research and Design participated in 
collection of data and had access to the raw data from a 
subset of the UK IPF patient data. LVW and RGJ were 
involved in all stages of study development and 
delivery, had full access to all data in the study, and had 
final responsibility for the decision to submit for 
publication.
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Chicago consortium Colorado consortium
65 excluded
   8 failed Affymetrix quality control
   6 heterozygosity outliers
   33 duplicates
   1 related*
   6 ancestry outliers
   6 did not have IPF
   5 sex mismatches
612 patients with IPF passed quality control
677 patients with IPF 502 682 individuals in UK Biobank
349 953 excluded because not genotyped
152 729 individuals with genotyped data
40 539 excluded
   480 missingness or heterozygosity 
   17 308 related*
   22 603 non-European
   148 people with interstitial lung disease
10 excluded for incomplete phenotype 112 190 individuals passed quality control
602 patients with IPF selected 3366 controls selected
3968 individuals included in discovery analysis
633 patients with IPF 
 recruited
58 excluded
 16 self-reported non-
 European ancestry
 28 call rate <97%
 10 sex mismatches
 4 related*
575 patients with IPF 
 passing quality 
 control
542 patients with IPF 
 selected after 
 genetic ancestry 
 matching
1054 individuals in analysis
118 excluded
      26 self-reported non-
 European ancestry
 69 call rate <97%
 18 sex mismatches
 5 related* 
1427 controls passing 
 quality control
542 controls selected 
 after genetic 
 ancestry matching
30 excluded for incomplete 
 phenotypes
7353 individuals in stage 2 meta-analysis
   2158 patients with IPF
   5195 controls
1914 patients with IPF 
 recruited
4828 controls recruited1545 controls recruited
298 excluded
 14 genetic outliers
 126 related*
 8 high heterozygosity
 150 call rate <98% 
145 excluded†
 41 sex mismatches
 105 call rate <98% 
6299 individuals in analysis
4683 controls passing 
 quality control
A
B
33 excluded because they 
 could not be genetically
      matched to controls
885 excluded because they 
 could not be genetically
         matched to patients
1616 patients with IPF 
            passed quality control
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Results
After sample quality control testing and genotype 
imputation, 602 patients with IPF and 3366 UK Biobank 
controls (selected on April 18, 2016) were included in the 
stage 1 analysis of 13 076 821 variants (figure 1A). The 
patients were diagnosed between June, 1996, and 
July, 2013, with the exception of 52 patients who were 
historical cases with unknown dates of diagnosis. In 
total, 44 independent signals were associated with 
susceptibility to IPF (p<5 × 10–⁶) and were followed up in 
stage 2 (figure 2).
A total of 2158 patients with IPF and 5195 controls were 
included in stage 2 (figure 1B, table 1). Of the 44 variants 
identified in stage 1, data were available for 27 variants in 
one or both of the stage 2 studies (appendix pp 8–9). Of 
these 27 variants, three were significant (p<1·85 × 10–³, 
after Bonferroni correction for 27 tests) in stage 2, and 
had genome-wide significance (p<5 × 10–⁸) in the meta-
analysis of stage 1 and 2 together (table 2). A novel 
association for the single-nucleotide polymorphism 
(SNP) rs62025270, which was the most strongly 
associated SNP in a broad signal covering AKAP13 and 
kelch like family member 25 (KLHL25; figure 3), had 
genome-wide significance in the meta-analysis of stages 1 
and 2 (minor allele A; odds ratio [OR] 1·27 [95% CI 
1·18–1·37], p=1·32 × 10–⁹). This SNP was also significant 
in stage 2 alone after Bonferroni adjustment for 27 tests 
Figure 1: Quality control and sample selection flow chart
(A) Stage 1 genome-wide association study. (B) Stage 2 follow-up analyses. 
*On identification of a pair of individuals who were second-degree relatives 
or closer, one individual was excluded. IPF=idiopathic pulmonary fibrosis. 
†One patient had both call rate <98% and sex mismatch.
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Figure 2: Manhattan plot for the discovery genome-wide association study of IPF susceptibility
The x axis shows chromosomal position and the y axis shows –log10(p value) from the discovery (stage 1) case-control analysis. Green variants are those that reached 
genome-wide significance in the meta-analysis of stage 1 and 2 results (and any variant in linkage disequilibrium with the lead variant [r²>0·1]). The blue line shows the 
threshold used for selecting variants for stage 2 (p=5 × 10⁻⁶) and the red line shows genome-wide significance (p=5 × 10⁻⁸). Hollow circles show variants showing an 
association with genotyping array in the controls, and those that did not show an association with IPF in stage 2 (appendix pp 2 and 6). IPF=idiopathic pulmonary fibrosis.
Stage 1 Stage 2: Chicago consortium Stage 2: Colorado consortium
IPF (n=602) Controls (n=3366) IPF (n=542) Controls (n=512) IPF (n=1616) Controls (n=4683)
Age, years
Mean (SD) 70 (8·4) 65 (5·5) 68 (3·0) 63* (7·5) 66 (9·5) ··
Sex
Men 426 (71%) 2356 (70%) 385 (71%) 242 (47%) 1091 (68%) 2290 (49%)
Women 176 (29%) 1010 (30%) 157 (29%) 270 (53%) 525 (33%) 2393 (51%)
Data are n (%) unless otherwise stated. Age was not available for Colorado consortium controls. IPF=idiopathic pulmonary fibrosis. *Age data were only available for 103 individuals.
Table 1: Baseline characteristics of stage 1 and stage 2 samples
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(OR 1·22 [95% CI 1·11–1·33], p=9·96 × 10–⁶). The 95% 
credible set (a set of variants that was 95% likely to 
contain the causal variant) produced for this signal 
contained 113 variants (appendix pp 10–11). The other 
two genome-wide significant signals were previously 
reported variants in MUC5B (rs35705950) and DSP 
(rs2076295).10–12
We explored whether genotyping array differences 
could have influenced the association test result for SNP 
rs62025270. In the control–control comparison 
(appendix p 6), rs62025270 showed no association with 
the array (p=0·35, appendix p 12). We repeated the 
association analysis for rs62025270 restricted to controls 
who were genotyped on the same array as the patients 
(602 patients vs 1231 controls); the results were consistent 
with the original analysis (stage 1 OR 1·45, [95% CI 
1·20–1·74], p=1·19 × 10–⁴; meta-analysis OR 1·25 [95% CI 
1·17–1·33], p=1·86 × 10–⁸). We reimputed the region with 
only variants genotyped on both arrays using the new 
Haplotype Reference Consortium imputation reference 
panel;23 the results were again consistent with the original 
analysis (stage 1 OR 1·48 [95% CI 1·25–1·75], 
p=4·24 × 10–⁶; meta-analysis OR 1·27 [95% CI 1·19–1·35], 
p=1·55 × 10–⁹).
Previous GWAS9–12 reported 16 independent signals 
associated with susceptibility to IPF with genome-wide 
significance. In stage 1 of our study, which analysed 
previously unreported data only, nine of these signals 
had a p value less than 0·05 and a direction of effect 
consistent with the previously reported effects. Further-
more, seven signals met a Bonferroni adjusted 
significance threshold for 16 tests (p<3·13 × 10–³) with a 
Chr Position Locus Minor 
allele
Major 
allele
MAF Stage 1 Stage 2 Meta-analysis (stages 1+2)
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
rs2076295 6 7563232 DSP G T 46·3% 1·67 (1·44–1·92) 4·14 × 10⁻¹² 1·39 (1·29–1·50) 2·47 × 10⁻¹⁸ 1·44 (1·35–1·54) 7·81 × 10⁻²⁸
rs35705950 11 1241221 MUC5B T G 14·3% 4·11 (3·31–5·11) 1·86 × 10⁻³⁷ 2·46 (2·13–2·85) 3·13 × 10⁻³⁴ 2·89 (2·56–3·26) 1·12 × 10⁻⁶⁶
rs62025270 15 86300198 AKAP13/KLHL25 A G 24·7% 1·49 (1·26–1·76) 3·11 × 10⁻⁶ 1·22 (1·11–1·33) 9·96 × 10⁻⁶ 1·27 (1·18–1·37) 1·32 × 10⁻⁹
Results from case-control analyses for the variants that were significant (after correction for multiple testing) in stage 2 and reached genome-wide significance in the meta-analysis of stages 1 and 2. MAF 
corresponds to that from the stage 1 study. ORs were calculated using the minor allele as the effect allele. Stage 2 ORs and p values correspond to the meta-analysis of the Chicago and Colorado consortia results.
Chr=chromosome. MAF=minor allele frequency. OR=odds ratio.
Table 2: Gene variants with genome-wide significance for idiopathic pulmonary fibrosis
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Figure 3: Comparison of case-control association results and lung eQTL results
Region plots for a 2 Mb region on chromosome 15 for the stage 1 case-control GWAS (circles above the x axis) and lung eQTL analysis (squares below the x axis). 
The x axis shows chromosomal position. The y axis above the x-axis shows the –log10(p value) from the case-control analysis and the y axis below the x axis shows the 
–log10(p value) for AKAP13 expression from the lung eQTL analysis. The blue dotted line shows the significance threshold (p=5 × 10⁻⁶) used in stage 1 and the red 
dotted line shows genome-wide significance (p=5 × 10⁻⁸). Boxes at the bottom show gene locations plotted against the same x axis as the case-control and eQTL 
results, with AKAP13 highlighted in green. Variants are coloured according to linkage disequilibrium with rs62025270 (shown in blue). eQTL=expression quantitative 
trait locus. GWAS=genome-wide association study.
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consistent direction of effect to previous GWAS; namely 
variants in MUC5B, DSP, family with sequence similarity 
13 member A (FAM13A), TERT, mucin 2 (MUC2), DPP9, 
and TOLLIP (appendix p 13). Five of the remaining 
seven signals that were not significant had a consistent 
direction of effect with previous GWAS.
SNP rs62025270[A] was associated with increased 
expression of AKAP13 in the lung. To identify the 
functional consequence of the rs62025270 
polymorphism, we assessed associations between 
rs62025270 and nearby variants and expression of genes 
(eQTLs). In non-diseased whole-lung tissue from the 
lung eQTL databases (University of British Columbia 
n=339, Laval n=409, and Groningen n=363), the minor 
allele A of rs62025270, associated with increased 
susceptibility to IPF, was associated with increased 
expression of AKAP13 (figure 4). SNP rs62025270 is in 
linkage disequilibrium (r²=0·60) with rs17636666, the 
variant that was most significantly associated with 
expression of AKAP13 in lung tissue. This co-localisation 
of IPF susceptibility association signal and strongest 
AKAP13 gene expression association signal (eQTL) in 
lung tissue (figure 3) further suggests that altered 
expression of AKAP13 has a role in IPF susceptibility. 
The minor allele A of rs62025270 (via proxy SNP rs2554, 
r²=0·93) was also associated with expression of AKAP13 
in whole blood (n=5311; appendix pp 7 and 14), although 
it was not in linkage disequilibrium (r²=0·03) with the 
SNP most strongly associated with AKAP13 expression 
in blood (rs870689). This finding suggests differences in 
regulation of AKAP13 expression between lung and 
whole blood, which have different cell-type 
compositions. Furthermore, the minor allele A of 
rs62025270 was associated with decreased expression of 
AKAP13 in blood, rather than increased expression as 
seen in lung tissue. The SNP rs62025270 was also found 
to be associated with expression of RNA genes RP11–
158M2.3, RP11–158M2.4, RP11–158M2.5, RP11–815J21.3, 
and RP11–815J21.4 in a range of tissues in GTEx 
(appendix p 14).
Having identified that the minor allele A of rs62025270 
was associated with increased susceptibility to IPF and 
increased expression of AKAP13 in lung tissue, we did a 
further analysis in lung tissue to identify the cellular 
location of AKAP13 in the lung and compared levels of 
AKAP13 mRNA from patients with IPF versus controls. 
Morphological assessment of histological sections from 
10 control and 10 patients with IPF showed that AKAP13 
protein was expressed primarily in bronchial epithelium 
(figure 5A) and alveolar type 1 and 2 cells (figure 5B) in 
control lung samples. High AKAP13 expression was 
observed in fibrotic regions of lung tissue from patients 
with IPF, and the cells expressing AKAP13 were primarily 
epithelial cells, macrophages, and lymphoid aggregates 
(figure 5C–F). High AKAP13 expression was also seen in 
epithelial cells from less fibrotic alveolar regions of lungs 
of patients with IPF, with more AKAP13-expressing cells 
in alveoli of patients with IPF (figure 5G) than in alveoli 
of controls (figure 5H). Real-time PCR analysis of samples 
from 46 patients with IPF and 51 controls established that 
concentrations of AKAP13 mRNA were 1·42-times higher 
in whole lung tissue homogenates from patients with IPF 
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Figure 4: Lung eQTL results for AKAP13 expression by rs62025270 genotype
Three independent datasets are shown. Blue points show normalised residuals of expression of AKAP13 after adjusting for age, sex, and smoking status for each 
individual by genotype of rs62025270. The box and whiskers show the mean and IQR for each genotype (left-hand y-axis). The grey boxes show the percentage of 
variance of AKAP13 expression that is explained by rs62025270 (right-hand y-axis). The p value relating the genotype to expression is shown at the top for each 
sample. Red allele indicates the allele associated with increased IPF susceptibility. eQTL=expression quantitative trait locus.
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than in lung tissue from controls (p=0·0011; figure 5I). 
Linear regression analysis confirmed that the significant 
increase in AKAP13 mRNA expression in lung tissue of 
patients with IPF was maintained after controlling for 
age, sex, and smoking history (p=2·03 × 10–⁴).
We tested the association of rs62025270 with survival 
time in all patients from stage 1 for whom survival 
data were available (n=565; 360 with recorded deaths and 
205 with censored survival times, with a minimum 
follow-up time of 1112 days before censoring). The 
median survival time after diagnosis of IPF was 1621 days 
(4·4 years; IQR 764–2815 days). rs62025270 showed no 
association with survival time (hazard ratio 1·01 [95% CI 
0·86–1·19], p=0·878).
11 proteins that interact with AKAP13 were identified 
as known targets for existing drugs or compounds in 
development, including aspirin, dextromethophan, and 
GSK-690693 (appendix pp 15–17).
Discussion
We studied 2760 patients with IPF and 8561 controls 
and identified a novel genome-wide significant 
association of variant rs62025270 that implicates 
AKAP13 as a potential driver of IPF pathogenesis. We 
showed that the minor allele (A) of rs62025270 (minor 
allele frequency [MAF]=25%), associated with increased 
susceptibility to IPF, was associated with increased 
expression of AKAP13 in lung tissue. Morphological 
analysis of control and diseased lung tissue identified 
AKAP13 expression primarily in epithelial cells, with 
some additional expression in lymphoid tissue in 
patients with IPF. Furthermore, we showed increased 
expression of AKAP13 in fibrotic lung tissue from 
patients with IPF compared with samples from healthy 
controls.
The high AKAP13 expression in epithelial cells further 
supports the hypothesis that IPF is a disease 
characterised by epithelial susceptibility to injury, 
consistent with findings of other genetic risk factors 
associated with epithelial cell function.13 AKAP13 is a 
RhoA guanine nucleotide exchange factor (RhoGEF) 
that is crucial for murine cardiac development. AKAP13-
null mice are embryonic lethal because of arrested 
cardiac development at embryonic day 10.24 Conversely, 
enhanced AKAP13 signalling has been shown to 
promote profibrotic signals in cardiac fibroblasts25 and 
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Figure 5: AKAP13 expression in bronchial mucosa and alveolar cells in 
patients with IPF and controls
Sections of lung tissue from controls show AKAP13 expression in the bronchial 
mucosa (A) and alveolar cells (B). Sections of lung tissue from patients with IPF 
show low AKAP13 expression in fibroblastic foci (C), and high expression in the 
epithelium lining fibrotic alveoli (D) and distal small airways (green arrow; E). 
(F) Strong staining in lymphoid follicles associated with fibrotic regions in patients 
with IPF. (G) Section of lung tissue from a patient with IPF showing that areas of 
lung less affected by fibrosis have high numbers of alveolar cells expressing 
AKAP13 (green arrows). (H) In tissue from regions of the lung unaffected by 
fibrosis in patients with IPF, type 1 (green arrows) and type 2 (blue arrow) alveolar 
epithelial cells primarily express AKAP13 in the parenchyma. (I) AKAP13 mRNA 
expression in whole lung tissue homogenates from patients with IPF and controls. 
Each point shows a sample from one person and the line shows the mean fold 
change (black bars show ± SE) in AKAP13 mRNA in 46 patients with IPF and 
51 controls. Relative expression (relative to housekeeping gene) is plotted on a 
log₂ scale. AKAP13=A-kinase anchoring protein 13. FF=fibroblastic foci. 
IPF=idiopathic pulmonary fibrosis. LF=lymphoid follicle.
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leads to cardiac hypertrophy in mice.26 Although 
AKAP13 has not previously been implicated in the 
pathogenesis of IPF, it plays a key role in profibrotic 
signalling pathways. Thrombin and lysophosphatidic 
acid have been identified as key profibrotic mediators 
acting via a Gq and RhoA signalling pathway in 
epithelial cells to promote αvβ6 integrin-mediated 
transforming growth factor β (TGFβ) activation.27,28 
AKAP13 coordinates thrombin and lysophosphatidic 
acid receptor signalling through Ga12 to RhoA in 
fibroblasts29 and astrocytes,30 and has also been shown to 
functionally interact with Gq, promoting RhoA 
activation.31–33 Therefore, AKAP13 might promote 
epithelial αvβ6 integrin-mediated TGFβ activation in 
response to epithelial injury, thereby promoting IPF. 
A phase 2 clinical trial assessing the safety and 
tolerability of a humanised monoclonal antibody 
directed against the αvβ6 integrin heterodimer 
(compound BG00011, formerly known as STX-100) in 
participants with IPF is underway (NCT01371305).
We also identified AKAP13 in lymphoid follicles within 
fibrotic regions of lung tissue from patients with IPF. 
Lymphoid follicles without germinal centres are well 
described in IPF and are thought to be composed 
primarily of B cells and dendritic cells.34–38 Increased 
concentrations of plasma B lymphocyte stimulating 
factor have been reported in patients with IPF compared 
with either controls or patients with chronic obstructive 
pulmonary disease, and higher concentrations were 
associated with severe disease.39 Furthermore, analysis of 
gene expression profiles from lymphoid follicles 
identified them as the source of C-X-C motif chemokine 
ligand 13,38 a biomarker of severe IPF,38,40 suggesting that 
lymphoid follicles might play an important undefined 
role in the pathogenesis of IPF. The role of AKAP13 in 
B-cell function is similarly poorly understood, although it 
has been shown to be responsible for glucocorticoid 
responsiveness in lymphocytes stimulated with 
lysophosphatidic acid,41 and is involved in lymphocyte 
responses to osmotic stress.42
Because of the known function of AKAP13, it probably 
has some potential downstream molecular interactions 
that could be targeted therapeutically, most notably RhoA 
and Rho kinase.43 11 proteins that interact with AKAP13 
were identified as known targets for existing drugs or 
compounds in development (appendix pp 15–17). One of 
the existing drugs was aspirin, which targets prostaglandin-
endoperoxide synthase 1 (PTGS1) and PTGS2, and PTGS2 
has a well described role in the pathogenesis of IPF.44–47 
Another of the drugs was dextromethorphan, a well 
known cough-suppressant that antagonises N-methyl-D-
aspartate receptors.48 Notably, a novel pan AKT inhibitor, 
GSK-690693, was also identified as a possible asset for 
targeting AKAP13 binding partners, and the AKT pathway 
is emerging as an important pathway in fibrogenesis.49
To our knowledge this is the first GWAS implicating 
AKAP13 at genome-wide significance in IPF 
susceptibility.12 Additionally, we confirmed seven 
previously reported associations with IPF susceptibility: 
the T allele of SNP rs35705950 in the MUC5B promoter 
(stage 1 p=1·86 × 10–³⁷) was the strongest genetic risk 
factor for susceptibility to IPF with an OR of 4·11,50 then 
DSP (stage 1 p=4·14 × 10–¹²), MUC2 (stage 1 
p=1·33 × 10–⁵), TOLLIP (stage 1 p=1·60 × 10–⁵), TERT 
(stage 1 p=8·25 × 10–⁵), DPP9 (stage 1 p=4·17 × 10–⁴), and 
FAM13A (stage 1 p=0·002). 17 variants were identified 
in stage 1 that have not been previously reported to be 
associated with IPF (of which 14 were low frequency or 
rare), but we could not investigate all of these in the 
stage 2 analyses because not all data were available. 
These could be additional true positive signals of 
association with susceptibility to IPF that will reach 
genome-wide significance in larger and more densely 
imputed studies.
A strength of our study is that we were able to bring 
together the largest sample size of patients with IPF and 
controls available to date and apply a robust and widely 
used two-stage study design10,11,51 to identify a novel 
genetic signal of association with IPF susceptibility. 
Furthermore, our stage 1 study samples were genotyped 
using the Affymetrix Axiom UK BiLEVE and UK 
Biobank arrays, which are optimised for imputation of 
individuals with European ancestry, and were genome-
wide imputed using the most comprehensive imputation 
panel resource available at the time. This enabled 
analysis of 13 076 821 variants genome-wide with MAF of 
more than 0·1%.
This study also has some limitations. Although clinical 
investigators were careful to exclude other fibrotic lung 
diseases, a small number of non-IPF cases of pulmonary 
fibrosis might have been included. However, the 
advantage of collating a large dataset is that the effects of 
misclassification on the analysis are reduced. 
Furthermore, we expect that misclassification would lead 
to attenuation of signals rather than produce false-
positive findings, which was supported by our replication 
of nine previously reported signals of association with 
IPF in our previously unreported stage 1 data. This 
included five signals that reached a Bonferroni-adjusted 
significance threshold for 16 tests (p<3·13 × 10–³), and two 
additional signals that reached genome-wide significance 
(MUC5B p=1·86 × 10–³⁷ and DSP p=4·14 × 10–¹²). In 
addition, the diagnostic practices between the UK and 
USA might be different but the concordant results from 
the three case-control studies reassures us that these 
observations are robust.
A previous study of 119 patients with IPF and 50 donor 
lung controls from the Lung Tissue Resource 
Consortium reported a small decrease of AKAP13 
expression in patients with IPF compared with controls 
using gene expression data from the Affymetrix Gene 
ST1·0 array;52 whereas our data using RT-PCR showed a 
moderate increase of AKAP13 expression in patients 
with IPF compared with controls. The discordance 
Articles
878 www.thelancet.com/respiratory   Vol 5   November 2017
between these results could be due to a number of 
factors, including the difference in normalisation 
strategies between the two techniques and sample 
heterogeneity. The eQTL data that we present from 
control lung tissue shows that the minor allele A of 
rs62025270, associated with susceptibility to IPF, is also 
associated with increased expression of AKAP13 in three 
independent studies.53–55 The immunohistochemistry 
results provide evidence that the predominant cell types 
expressing AKAP13, in both normal and fibrotic lung, 
are epithelial cells and resident immune cells, whereas 
the dense fibrotic regions of lung with an expanded 
population of myofibroblasts (figure 5C–F) do not 
express AKAP13. Furthermore, eQTL data from whole 
blood reveals the minor allele A of rs62025270 is 
associated with reduced expression of AKAP13 mRNA. 
Therefore, these data provide strong independent 
evidence that increased AKAP13 expression in alveolar 
cells has a role in IPF, and the cellular heterogeneity 
within the fibrotic lung samples used for RNA analysis 
is likely to explain this discordance.
In summary, we report a novel genome-wide significant 
association for IPF susceptibility with SNP rs62025270 
and present evidence that this SNP might exert its effect 
via expression of the nearby gene AKAP13. AKAP13 is a 
RhoGEF that is known to interact with a central 
fibrogenic pathway—G protein-coupled receptor 
activation of RhoA—and expression is increased in 
fibrotic regions of lungs from patients with IPF. 
Expression of AKAP13 occurs primarily in the epithelium 
thereby reinforcing the idea that epithelial processes are 
central to IPF pathogenesis. The identification of a 
RhoGEF that regulates a pathway known to be involved 
in the pathogenesis of IPF, a pathway for which drugs 
are in development, could potentially provide a novel 
target for antifibrotic therapy for IPF.
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